Skip Navigation

Rheumatology 2008 47(Supplement 5):v2-v4; doi:10.1093/rheumatology/ken265
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Trojanowska, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trojanowska, M.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

This article appears in the following Rheumatology issue: Update in systemic sclerosis [View the issue table of contents]

Role of PDGF in fibrotic diseases and systemic sclerosis

M. Trojanowska1

1Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA.

Correspondence to: M. Trojanowska, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA. E-mail: trojanme{at}musc.edu


  Abstract

PDGF functions as a primary mitogen and chemoattractant for cells of mesenchymal origin. Members of the PDGF family play an important role during embryonic development and contribute to the maintenance of connective tissue in adults. Deregulation of PDGF signalling has been linked to atherosclerosis, pulmonary hypertension and organ fibrosis. Elevated expression of PDGF and its receptors has been found in scleroderma skin and lung tissues. There is evidence for a TGF-β and IL-1{alpha}-dependent autocrine PDGF-A/PDGFR{alpha} signalling loop in scleroderma skin and lung fibroblasts, suggesting that a cross-talk between TGF-β and PDGF pathways may regulate chronic fibrosis in scleroderma.

KEY WORDS: Platelet-derived growth factor, Platelet-derived growth factor receptor, Transforming growth factor-β, Fibrosis, Pulmonary arterial hypertension, Scleroderma, Myofibroblast

Submitted 30 April 2008; Accepted 18 June 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.